Latest & greatest articles for Topical Corticosteroid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Topical Corticosteroid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Topical Corticosteroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Topical Corticosteroid

1. Seborrhoeic dermatitis: Topical corticosteroids

Seborrhoeic dermatitis: Topical corticosteroids Topical corticosteroids | Prescribing information | Seborrhoeic dermatitis | CKS | NICE Search CKS… Menu Topical corticosteroids Seborrhoeic dermatitis: Topical corticosteroids Last revised in February 2019 Topical corticosteroids For detailed information on prescribing corticosteroids see the CKS topic on . © .

2020 NICE Clinical Knowledge Summaries

2. Scabies: Topical corticosteroids

Scabies: Topical corticosteroids Topical corticosteroids | Prescribing information | Scabies | CKS | NICE Search CKS… Menu Topical corticosteroids Scabies: Topical corticosteroids Last revised in November 2017 Topical corticosteroids Contraindications, adverse effects, dosing information For detailed information on prescribing topical corticosteroids, please see the CKS topic on . © .

2018 NICE Clinical Knowledge Summaries

3. Corticosteroids - topical (skin), nose, and eyes: Scenario: Topical treatment

effects of oral corticosteroids may also occur with topical corticosteroids, especially in children, including: Adrenal suppression — for signs and symptoms of adrenal suppression, see the section on in the CKS topic on . Cushing's syndrome. Growth suppression. Visual disturbance — if a person presents with symptoms such as blurred vision or other visual disturbances, consider referral to an ophthalmologist for evaluation of possible causes that may include cataract, glaucoma, or rare diseases (...) review Choosing topical corticosteroids [ ], and the summary of product characteristics for Betnovate cream [ ]. Systemic adverse effects An Australasian College of Dermatology consensus statement on the adverse effects of topical corticosteroids in paediatric eczema [ ] states that physiological hypothalamic-pituitary-adrenal (HPA) axis suppression can occur with very widespread and prolonged, or occlusive use of potent/superpotent topical corticosteroids. However, this recovers quickly

2018 NICE Clinical Knowledge Summaries

4. Corticosteroids - topical (skin), nose, and eyes: Scenario: Intranasal corticosteroid treatment

burning, irritation, ulceration. Systemic adverse effects — these occur rarely, are much less likely to occur than with oral corticosteroids, and are associated with high doses or prolonged treatment. The risk is higher with drops compared with sprays, as they are administered incorrectly more frequently. Systemic adverse effects include: Adrenal suppression — for signs and symptoms of adrenal suppression, see the section on in the CKS topic on . Cushing's syndrome. Decreased bone mineral density (...) Corticosteroids - topical (skin), nose, and eyes: Scenario: Intranasal corticosteroid treatment Scenario: Intranasal corticosteroid treatment | Management | Corticosteroids - topical (skin), nose, and eyes | CKS | NICE Search CKS… Menu Scenario: Intranasal corticosteroid treatment Corticosteroids - topical (skin), nose, and eyes: Scenario: Intranasal corticosteroid treatment Last revised in June 2020 Scenario: Intranasal corticosteroid treatment From birth onwards. What should I consider when

2018 NICE Clinical Knowledge Summaries

5. Corticosteroids - topical (skin), nose, and eyes: Scenario: Eye treatment

characteristics state that there is inadequate data to determine the safety of corticosteroid eye preparations in pregnancy [ ; ]. With systemic use of corticosteroids at higher doses, intrauterine growth inhibition and inhibition of the function of the adrenal cortex have been reported, but these effects have not been reported for ocular use [ ]. Topical administration of corticosteroids to pregnant animals can cause abnormalities of fetal development including cleft palate and intrauterine growth (...) with high doses prescribed for prolonged periods. Systemic adverse effects include: Adrenal suppression — for signs and symptoms of adrenal suppression, see the section on in the CKS topic on . Cushing's syndrome. Visual disturbance, central serous chorioretinopathy, cataract, glaucoma. If a person presents with symptoms such as blurred vision or other visual disturbances, consider referral to an ophthalmologist for evaluation. For more information on the systematic adverse effects of corticosteroids

2018 NICE Clinical Knowledge Summaries

6. Corticosteroids - topical (skin), nose, and eyes

Corticosteroids - topical (skin), nose, and eyes Corticosteroids - topical (skin), nose, and eyes | Topics A to Z | CKS | NICE Search CKS… Menu Corticosteroids - topical (skin), nose, and eyes Corticosteroids - topical (skin), nose, and eyes Last revised in June 2020 Corticosteroids are synthetic analogues of the natural hormones that are produced by the adrenal cortex. Management Background information Corticosteroids - topical (skin), nose, and eyes: Summary Corticosteroids are synthetic (...) analogues of the natural hormones that are produced by the adrenal cortex. Local corticosteroids are predominantly glucocorticoids. They have four main effects: Anti-inflammatory. Immunosuppressive. Anti-proliferative (anti-mitotic). Vasoconstrictive. Topical corticosteroids exert these effects on the skin: Eczema — the anti-inflammatory and immunosuppressive effects are important. Psoriasis — is characterized by rapid cell turnover, and the anti-mitotic effects are important. Intranasal corticosteroids

2018 NICE Clinical Knowledge Summaries

7. Topical Corticosteroids Improve Healing Time in Patients with Aphthous Ulcers

. Applicability The evidence, while of low quality, still supports the application of topical corticosteroids to reduce the healing time of aphthous ulcers. The studies also report a reduction in the occurrence of new ulcers, the size of the ulcers, and the pain experienced by the patient due to the ulcers. A study evaluated in the systematic review shows that topical corticosteroids used intraorally do not cause adrenal suppression, if the patient uses them as instructed. Specialty/Discipline (Oral Medicine (...) Topical Corticosteroids Improve Healing Time in Patients with Aphthous Ulcers UTCAT3273, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Topical Corticosteroids Improve Healing Time in Patients with Aphthous Ulcers Clinical Question In patients with aphthous ulcers, does treatment with topical corticosteroids, as compared to a placebo, improve healing time of the ulcers? Clinical Bottom Line Patients treated

2017 UTHSCSA Dental School CAT Library

8. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. (Abstract)

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Dupilumab (an anti-interleukin-4-receptor-α monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis. Previous 16-week monotherapy studies showed that dupilumab (...) substantially improved signs and symptoms of moderate-to-severe atopic dermatitis with acceptable safety, validating the crucial role of interleukin 4 and interleukin 13 in atopic dermatitis pathogenesis. We aimed to evaluate the long-term efficacy and safety of dupilumab with medium-potency topical corticosteroids versus placebo with topical corticosteroids in adults with moderate-to-severe atopic dermatitis.In this 1-year, randomised, double-blinded, placebo-controlled, phase 3 study (LIBERTY AD CHRONOS

2017 Lancet Controlled trial quality: predicted high

10. Psoriasis patients’ experiences concerning medical adherence to treatment with topical corticosteroids Full Text available with Trip Pro

Psoriasis patients’ experiences concerning medical adherence to treatment with topical corticosteroids Nonadherence to topical treatment of psoriasis is a common cause of treatment failure. This focus group study was conducted to obtain the patients' own experiences and explanations regarding medical adherence. The participants consisted of eight primary adherent patients with moderate psoriasis treated with corticosteroid or corticosteroid-calcipotriol combinations, purposefully sampled (...) in the prescriber, diverging information from health care personnel, experiencing side effects, having fear of side effects, impractical formulations of topical products, and impatience regarding time before an effect of the treatment was observed. From this study, the recommendations for the prescribing doctor to improve medical adherence are, the doctor needs to take time to listen to the patient, prescribe a topical product that is easy to apply and less greasy, inform the patients about benefits from

2016 Psoriasis (Auckland, N.Z.)

11. Systematic review: Best evidence supports topical corticosteroids and routine saline irrigations for medical treatment of chronic rhinosinusitis

Systematic review: Best evidence supports topical corticosteroids and routine saline irrigations for medical treatment of chronic rhinosinusitis Best evidence supports topical corticosteroids and routine saline irrigations for medical treatment of chronic rhinosinusitis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Best evidence supports topical corticosteroids and routine saline irrigations for medical treatment of chronic

2016 Evidence-Based Medicine

12. Pruritus vulvae: Topical corticosteroids

Pruritus vulvae: Topical corticosteroids Topical corticosteroids | Prescribing information | Pruritus vulvae | CKS | NICE Search CKS… Menu Topical corticosteroids Pruritus vulvae: Topical corticosteroids Last revised in May 2017 Topical corticosteroids See the in the CKS topic on . © .

2016 NICE Clinical Knowledge Summaries

13. Pityriasis rosea: Topical corticosteroids

Pityriasis rosea: Topical corticosteroids Topical corticosteroids | Prescribing information | Pityriasis rosea | CKS | NICE Search CKS… Menu Topical corticosteroids Pityriasis rosea: Topical corticosteroids Last revised in April 2020 Topical corticosteroids For prescribing information on topical corticosteroids, including application advice and minimization of adverse effects, see the CKS topic on . © .

2016 NICE Clinical Knowledge Summaries

14. Topical corticosteroids effective for nasal polyps

Topical corticosteroids effective for nasal polyps Topical corticosteroids effective for nasal polyps | Cochrane Primary Care Trusted evidence. Informed decisions. Better health. Enter terms Topical corticosteroids effective for nasal polyps Cochrane Trusted evidence. Informed decisions. Better health. Copyright © 2019 The Cochrane Collaboration | | We use cookies to improve your experience on our site.

2013 Cochrane PEARLS

15. Safety of topical corticosteroids in pregnancy. (Abstract)

Safety of topical corticosteroids in pregnancy. Topical corticosteroids are the most frequently prescribed dermatological treatment and are frequently used by pregnant women with skin conditions. However, little is known about their safety in pregnancy.To assess the effects of topical corticosteroids on pregnancy outcomes.On 5th May 2009 we searched the Cochrane Skin Group Specialised Register, the Cochrane Pregnancy and Childbirth Group Specialised Register, CENTRAL (The Cochrane Library 2009 (...) , Issue 2), MEDLINE (from 2003), and EMBASE (from 2005). We searched LILACS, CINAHL, British Nursing Index, SCI-EXPANDED, BIOSIS Previews, Conference Papers Index, and Conference Proceedings Citation Index-Science from inception to May 2009. We scanned the bibliographies of the included studies, published reviews, and articles that had cited the included studies. Pharmaceutical companies that have introduced an original topical corticosteroid product were contacted.Randomised controlled trials

2009 Cochrane

16. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. Full Text available with Trip Pro

Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. To determine the clinical effectiveness of topical intranasal corticosteroids in children with bilateral otitis media with effusion.Double blind randomised placebo controlled trial.76 Medical Research Council General Practice Research Framework practices throughout the United Kingdom, between 2004 and 2007.217 (...) ) at one month (primary end point), three months, and nine months; adverse events; three month diary symptoms. Results 41% (39/96) of the topical steroid group and 45% (44/98) of the placebo group were cured in one or both ears at one month (difference favouring placebo 4.3% (95% confidence interval -9.3% to 18.1%). Poisson regression was done with adjustment for four pre-specified covariates (clinical severity, P=0.003; atopy, P=0.67; age, P=0.92; season, P=0.71). The adjusted relative risk at one

2009 BMJ Controlled trial quality: predicted high

17. A double-blind randomised placebo controlled trial of topical intranasal corticosteroids in 4- to11-year-old children with persistent bilateral otitis media with effusion in primary care

A double-blind randomised placebo controlled trial of topical intranasal corticosteroids in 4- to11-year-old children with persistent bilateral otitis media with effusion in primary care Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 Health Technology Assessment (HTA) Database.

18. Topical corticosteroids as adjunctive therapy for bacterial keratitis. Full Text available with Trip Pro

Topical corticosteroids as adjunctive therapy for bacterial keratitis. Bacterial keratitis is a serious ocular infectious disease that can lead to severe visual disability. Risk factors for bacterial corneal infection include contact lens wear, ocular surface disease, corneal trauma and previous ocular or eyelid surgery. Topical antibiotics constitute the mainstay of treatment in cases of bacterial keratitis where as the use of topical corticosteroids remains controversial. Topical (...) , an online database of ongoing trials (www.clinicaltrials.gov), reference lists of included trials, earlier reviews and the American Academy of Ophthalmology guidelines. We also contacted experts to identify any unpublished and ongoing randomized trials.We included randomized controlled trials evaluating adjunctive therapy with topical corticosteroids in people with bacterial keratitis.Two review authors independently screened all the retrieved articles. Methodological quality of the one included trial

2007 Cochrane

19. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema

A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema Pitt M, Garside R, Stein K Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of topical corticosteroids (TCS) as a first-line treatment followed by pimecrolimus as a second-line treatment, and pimecrolimus as a first-line treatment followed by TCS, in the treatment of mild and moderate atopic eczema. Type

2006 NHS Economic Evaluation Database.

20. Frequency of application of topical corticosteroids for atopic eczema (TA81)

Frequency of application of topical corticosteroids for atopic eczema (TA81) Overview | Frequency of application of topical corticosteroids for atopic eczema | Guidance | NICE Frequency of application of topical corticosteroids for atopic eczema Technology appraisal guidance [TA81] Published date: 25 August 2004 Share Guidance on using topical corticosteroids for people with atopic eczema. Guidance development process Is this guidance up to date? . We found nothing new that affects

2004 National Institute for Health and Clinical Excellence - Technology Appraisals